Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
about
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencingTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibImatinib: a breakthrough of targeted therapy in cancer.Practical management of patients with chronic myeloid leukemia.Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatmentNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaChronic myelogenous leukemia: treatment and monitoring.Monitoring response and resistance to treatment in chronic myeloid leukemia.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Chronic myeloid leukemia: mechanisms of resistance and treatment.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureHow I treat childhood CML.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Suboptimal responses in chronic myeloid leukemia: implications and management strategiesAlectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Management of imatinib-resistant patients with chronic myeloid leukemia.Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Treatment of chronic myeloid leukemia when imatinib fails.New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.Evolution of therapies for chronic myelogenous leukemia.Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Clinical trials in chronic myeloid leukemia.Treatment options for chronic myeloid leukemia.Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.Management options for refractory chronic myeloid leukemia: considerations for the elderly.BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.Chronic myeloid leukemia: Second-line drugs of choice.An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
P2860
Q27028181-17410304-7FEF-40B3-8D00-595E9B6DBA0CQ27851628-9AACEBA7-1282-4132-9C23-B6319C43C69AQ28534967-57355F3E-4B8F-4EA1-A3D9-FF724692AEE1Q30242015-997570A1-3B9A-4DE5-8DD6-A9E512D0F4FAQ33391185-C09E751B-2F16-4C46-80EC-FC9DCDC9804AQ33747261-DE63837A-5080-4708-90E3-D9A4A47462AFQ33849146-4C05A9B3-0EA1-4A96-944A-FE49931937A1Q33878636-66350238-46FF-4B09-BB72-2F2083E844FBQ33903030-5585F50F-227F-4C7E-8DDA-156A499ECB37Q34481214-32AE2FDB-BDE1-4056-909C-EFB7433A05CDQ34522789-2C6D094A-4490-413F-9EAD-0EA178D5427EQ34617628-2D665D02-D08D-4482-BAF0-E797111E7C9EQ34761663-AF5F58EE-E2D5-419A-AA66-84BB04B293F3Q34894883-5439314E-075C-41E7-9B57-BAC577F19529Q35595795-AD21602E-A71A-4097-9E95-786E63DD9F44Q35596200-40DFD393-312E-4D41-A041-FACF46222853Q35802202-3D3DF1DA-F2EC-4D55-AD11-47FBB3B863DAQ35930616-380782E3-C9C6-460E-A1A2-9861E92115FCQ36144079-56D7FF3A-4263-471D-9592-F500CF6D8942Q36550838-129E5A37-A602-4709-9F65-9260DCE515BDQ36734508-A0CE79C9-3282-48C1-AA20-591DE4FE932BQ36776423-4444C941-0636-4873-8372-EDDFDAA5179FQ37163550-204B9755-8762-4332-A6EE-01057C32E79EQ37607094-969252E2-2C2A-4FFC-AAF2-E77F4F37F91FQ37791429-BAEDCA41-F1E1-4AB1-AA0B-33588525A02FQ37827875-C8CCFFF8-B6DE-48BA-B1CE-A5122AA0E2CAQ37836938-74EE572A-CE12-4B8F-956E-FFEDFBA0A336Q37896606-9F2D5E7B-AE17-4492-98BA-D038E49B974FQ37966915-E3703042-952A-4832-A16F-585B9055EC08Q37988569-E57D6F53-B25B-4E68-A9C1-3AE750B423F6Q37994134-A9B4257F-A437-4EE1-8727-82EE51AA2A83Q37994805-96550A00-1460-442F-AD3A-46E7FEFDC009Q38037648-F3138C5F-D35D-413D-8A5B-68FE016ED328Q38101471-3858EE47-7126-4C6E-B040-912F668CAB5AQ38154292-E76681FB-AA27-4607-8ABB-3C2A0719D635Q38199143-DA879F50-6C1C-4F05-A3EE-0AB73B14555BQ38204330-FD5D000F-2EC1-4BB2-AC86-257B480B17EDQ38436037-7BAEA5ED-49D4-4E68-8588-B80D557C1C7DQ38640422-8EA5093B-CFE5-428A-892F-07B8888D50D6Q38672008-FB5FB01C-EE1D-4F99-BAB7-4D0E85E48709
P2860
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@ast
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@en
type
label
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@ast
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@en
prefLabel
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@ast
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@en
P2093
P2860
P50
P1433
P1476
Imatinib mesylate dose escalat ...... tandard-dose imatinib therapy.
@en
P2093
Jenny Shan
Neeli Reddy
P2860
P304
P356
10.1182/BLOOD-2008-04-154344
P407
P50
P577
2008-12-05T00:00:00Z